Direct Oral Anticoagulants (DOACs) consistently demonstrated a greater net clinical benefit compared to Vitamin K Antagonists (VKAs) also in persons aged 75 years and over, who account for the largest proportion of AF patients; however, major uncertainties in DOACs prescription have to do with this age group. In this review, persistent uncertainties and implications of frailty and geriatric syndromes on DOACs prescription, and practical use of DOACs in real-world older persons, and will be discussed.
Practical use of Direct Oral Anti Coagulants (DOACs) in the older persons with atrial fibrillation / Bo M.; Marchionni N.. - In: EUROPEAN JOURNAL OF INTERNAL MEDICINE. - ISSN 0953-6205. - ELETTRONICO. - 71:(2020), pp. 32-38. [10.1016/j.ejim.2019.10.026]
Practical use of Direct Oral Anti Coagulants (DOACs) in the older persons with atrial fibrillation
Marchionni N.
Writing – Original Draft Preparation
2020
Abstract
Direct Oral Anticoagulants (DOACs) consistently demonstrated a greater net clinical benefit compared to Vitamin K Antagonists (VKAs) also in persons aged 75 years and over, who account for the largest proportion of AF patients; however, major uncertainties in DOACs prescription have to do with this age group. In this review, persistent uncertainties and implications of frailty and geriatric syndromes on DOACs prescription, and practical use of DOACs in real-world older persons, and will be discussed.
| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S0953620519303784-main.pdf
Accesso chiuso
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Tutti i diritti riservati
Dimensione
544.25 kB
Formato
Adobe PDF
|
544.25 kB | Adobe PDF | Richiedi una copia |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
